EU-X-CT Public Stakeholders' Forum 2024

Making cross-border access to clinical trials a reality

Description

Event Workshop
Type Face To Face
Language English
Date(s) 12-04-2024
Day(s) 1 Day(s)
Duration 1 Days

The pan-European public-private EU-X-CT Initiative aims at facilitating cross-border access to clinical trials in concrete terms. We are collecting information on the regulatory, ethical, social security and organizational conditions for the involved stakeholders, experiences and best practices in all European countries.  This Public Stakeholders' Forum will be the opportunity to jointly review the national conditions for patients, clinical investigators, academia/public funders and industry sponsors in need for cross-border participation of patients in clinical trials. The EU-X-CT gap analysis will be the basis for our panel and open forum discussions to come to conclusions about most efficient European and national strategies and activities for improvements in the near and mid-term future.

 

Cannot join us on site? Follow this event online for free, please register by clicking HERE.
*Disclaimer: by attending the workshop for free via Zoom, it is not guaranteed that you will be able to interact directly with the Faculty.

With the Support of

Gold
Silver
Bronze

Programme

Friday 12 April 2024
09:00 Registration and welcome coffee
Session 1: Where are we today?
10:00 Introduction to EU-X-CT
Welcome from EFGCP and EFPIA
Ingrid Klingmann, Pharmaplex, EFGCP
Susan Bhatti, Merck Healthcare KGaA, EFPIA
Welcome from the academia members
Welcome from the patient members
Lisbeth Snede, Patient Advocate
10:20 Round table: Current experience with cross-border trial participation
Moderator(s): Lisbeth Snede, Patient Advocate
Michel Zwaan, Princess Maxima Centrum
TBA, Patient Representative
10:50 Keynote: Overcoming borders will make Europe a more attractive place for clinical trials
Elmar Nimmesgern, EU Commission DG R&I
11:20 The issues of cross-border access to clinical trials in Europe: The EU-X-CT gap analysis
Moderator(s): Susan Bhatti, Merck Healthcare KGaA
Lisbeth Snede, Patient advocate
Maja Pizevska, Berlin Institute of Health at Charité (BIH)
Maren Koban, Merck Healthcare KGaA
12:20 Panel and Open Forum Discussion: • Is this picture accurate and comprehensive? • Where are the assessment gaps? • How to close them? • Which other EU partnerships suffer from the lack of cross-border access to clinical trials?
Moderator(s): Solange Corriol-Rohou, AstraZeneca
Elmar Nimmesgern, EU Commission DG R&I
Emilie Prazaková, Roche
Janek Kapper, Estonian Inflammatory Bowel Disease Society
Marianne Lunzer, CTCG
Monique Al, Central Committee on Research Involving Human Subjects
13:00 Lunch
Session 2: Where do we want to go?
14:00 European needs in overcoming borders in clinical research
Moderator(s): Sabine Kläger, ECRIN
Bettina Ryll, Stockholm School of Economics Institute for Research
14:30 The way forward: how do we make progress in cross-border access to Clinical Trials?
Moderator(s): Bettina Ryll, Stockholm School of Economics Institute for Research
Elmar Nimmesgern, EU Commission DG R&I
Jacques Demotes, ECRIN
Marianne Lunzer, CTCG
Monique Al, Central Committee on Research Involving Human Subjects
Susan Bhatti, Merck Healthcare KGaA
15:30 Break
15:50 Open Forum Discussion: How can EU-X-CT achieve the most urgent goals and how to make them sustainable?
Moderator(s): Ingrid Klingmann, EFGCP
Susan Bhatti, Merck Healthcare KGaA
16:50 Conclusions and next steps
Moderator(s): Ingrid Klingmann, EFGCP
17:00 End of meeting